Bioconnect Systems, Inc. is pioneering novel surgical
implants and
techniques that form precisely controlled vascular connections.
The Optiflow™ family of sutureless anastomotic connectors provides
a fast and repeatable method for connecting vessels.
techniques that form precisely controlled vascular connections.
The Optiflow™ family of sutureless anastomotic connectors provides
a fast and repeatable method for connecting vessels.
While the technology is applicable to a wide range of
surgical procedures,
Bioconnect is initially focused on improving vascular access in End Stage
Renal Disease (ESRD) patients who undergo hemodialysis. There are over two
million patients suffering from ESRD. The American Society of Nephrology
and the US Renal Data System have called ESRD a "worldwide plague."
Bioconnect is initially focused on improving vascular access in End Stage
Renal Disease (ESRD) patients who undergo hemodialysis. There are over two
million patients suffering from ESRD. The American Society of Nephrology
and the US Renal Data System have called ESRD a "worldwide plague."
Optiflow™ is under investigation
and not available for sale.
Optiflow Technology
Optiflow technology is currently being utilized to improve the performance of arteriovenous fistulae and vascular access grafts. The Optiflow™ platform optimizes hemodynamics while minimizing vessel trauma.
Clinical Need
Long-term results for current vascular access methods are unacceptable. Vascular access is widely recognized as the Achilles Heel of dialysis. Recent studies demonstrate over 60% of newly created AVF access sites fail within the first 4-5 months while 77% of synthetic grafts fail within the first year.
Clinical Data
Initial clinical studies of the Optiflow technology have demonstrated favorable results. Phase II studies are currently underway.
